F3
Tissue factor
As of the edition of 20 October 2026, F3 (tissue factor, UniProt P13726) has 1 drug tested at it and 2 companies on the list, 0 on route A and 2 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P13726
- How well studied
- Drug target: an approved drug acts on it
- Solved structures
- 54
- Disease areas
- Cancer; Pregnancy and women's health; Urinary and reproductive; Hormones; Digestive system; Lungs and airways
- Registered trials of its drugs
- 12
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Total | 1 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Tisotumab vedotin | Marketed | Phase 4 | Ends 2033 |
1 of 1 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route B | 2 |
| Total on the list | 2 |
The other 0 companies at F3
In the product2 companies in all; 0 are not named here, and no score is.
See the 2 companies at F3, ranked, with the facts behind eachRequest access. Nothing is shown until you do.